SLC5A2 and type 2 diabetes mellitus: ,43 A previous study assessed the safety of SGLT2 inhibitors in older patients with type 2 diabetes and treatment discontinuation due to adverse events was found to be nearly twice as high in those aged ≥80 years compared with younger patients.44